Article
Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.
Neoplasia (New York, N.Y.) - 1 Jun 2026
Wu Sihan, Liu Hao, Yin Yuhan, Li Jiehan, Zhang Zhen, Li Wei, Fu Yang
Abstract excerpt
Gastrointestinal stromal tumors (GISTs), the most common mesenchymal neoplasms of the digestive tract, are primarily driven by mutations in KIT/PDGFRA. The remarkable success of tyrosine kinase inhibitors such as imatinib (IM) in treating GIST has established them as a paradigm of precision medicine in modern oncology. However, acquired resistance to IM remains a major cause of poor prognosis in GIST patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.